MR-guided ultrasound developer Insightec has signed a credit facility for up to $200 million with affiliates of existing shareholders to continue development of its Exablate technology.
The company secured $100 million at closing on September 1, with an additional $100 million of financing potentially available in tranches through 2024.
Insightec's Exablate Neuro system is designed to focus sound waves guided by MRI to target tremors in patients with medication-refractory essential tremor and Parkinson's disease. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions, the company said.
